AptaMatrix, Inc.

AptaMatrix, Inc.

AptaMatrix Inc. is a biotechnology firm leveraging next-gen sequencing technology to accelerate aptamer discovery. Aptamers are non-coding nucleic acid molecules that have the ability to bind to protein targets will high affinity and specificity. Aptamers are the nucleic acid equivalent of a monoclonal antibody, and viable as therapeutic agents and for detection/diagnostic applications. Using AptaMatirx's proprietary workflow, aptamer discovery can be reduced to 2 weeks with an anticipated reduction to 3 days. AptaMatrix specializes in screening modified nucleic acid libraries that are difficult to screen using traditional SELEX aptamer discovery methods.

Visit Site